Canadian Journal of Infectious Diseases, 1992 The universal response surface approach (URSA) was developed to assess the nature and intensity of drug interactions, ie, synergism. antagonism and additivity.
William R Greco, Wlodzimierz E Dembinski
doaj +1 more source
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. [PDF]
, 2016 mTOR inhibition has emerged as a promising strategy for head and neck squamous cell carcinomas (HNSCC) treatment. However, most targeted therapies ultimately develop resistance due to the activation of adaptive survival signaling mechanisms limiting the ...
Amornphimoltham, Panomwat +10 more
core +1 more source
Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. [PDF]
, 2019 Fluoroquinolones represent the pillar of multidrug-resistant tuberculosis (MDR-TB) treatment, with moxifloxacin, levofloxacin, or gatifloxacin being prescribed to MDR-TB patients.
Alvarez-Cabrera, Nadine +16 more
core +2 more sources
Frontiers in Oncology, 2021 Angiosarcoma is a rare cancer of blood vessel–forming cells with a high patient mortality and few treatment options. Although chemotherapy often produces initial clinical responses, outcomes remain poor, largely due to the development of drug resistance.
Jhuma Saha +15 more
doaj +1 more source
The phytocannabinoid, Δ(9) -tetrahydrocannabivarin, can act through 5-HT1 A receptors to produce antipsychotic effects [PDF]
, 2015 Funded by: •GW Pharmaceuticals Acknowledgements: The authors wish to thank Mrs Lesley Stevenson for technical support and Dr John Raymond, Dr Keith Parker and Dr Ethan Russo for providing human 5-HT1A CHO cells.
Cascio, Maria Grazia +4 more
core +1 more source
Erythrocytes as Carriers of Therapeutic Enzymes. [PDF]
, 2020 Therapeutic enzymes are administered for the treatment of a wide variety of diseases. They exert their effects through binding with a high affinity and specificity to disease-causing substrates to catalyze their conversion to a non-noxious product, to ...
Bax, BE
core +1 more source
Pharmacology Research & Perspectives, 2022 G protein‐coupled receptors (GPCRs) are valuable therapeutic targets for many diseases. A central question of GPCR drug discovery is to understand what determines the agonism or antagonism of ligands that bind them.
Mireia Jiménez‐Rosés +13 more
doaj +1 more source
Evaluation of Small Molecule Combinations against Respiratory Syncytial Virus In Vitro
Molecules, 2021 Respiratory syncytial virus (RSV) is a major pathogen that causes severe lower respiratory tract infection in infants, the elderly and the immunocompromised worldwide. At present no approved specific drugs or vaccines are available to treat this pathogen.
Yuzhen Gao +4 more
doaj +1 more source
9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one is a potentially novel antiplatelet drug which antagonizes the effect of thromboxane A2 [PDF]
, 2018 Background: Currently, used oral antiplatelet drugs are both limited and associated with the risk of treatment failure/resistance. Research in this area is hence highly desired.
Applová, Lenka +8 more
core +1 more source
Questions about Chemokine and Chemokine Receptor Antagonism in Renal Inflammation [PDF]
, 2010 Chemokines remain attractive therapeutic targets for modulating inflammatory diseases in all areas of medicine including acute and chronic kidney disease.
Anders, Hans-Joachim +2 more
core +1 more source